Elizabeth Garner, MD, MPH has over a decade of pharmaceutical development experience. She also has deep expertise in clinical trial design and execution. She has held roles of increasing strategic responsibility in large and small companies, including ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. In addition to Pharm-Olam, she is also on the Boards of the Drug Information Association (DIA) and the American Medical Women’s Association (AMWA), and she was a 2019 awardee of the PharmaVoice 100 most inspiring individuals in the life-sciences industry.
Dr. Garner is currently the Chief Medical Officer at ObsEva, a biopharmaceutical company that focuses on the development of treatments as therapies centered on women’s reproductive health and pregnancies. She is also the Owner and President of KNI Health Consultants, LLC, where she offers therapeutic consultations and insights on regulatory affairs. Dr. Garner serves as a member of the Board of Directors (Audit Committee) of Kezar Life Sciences (KZR). Prior to her role at ObsEva, Dr. Beth Garner was the Chief Medical Officer at Agile Therapeutics, where she led the company’s clinical development, regulatory, and medical affairs strategies while managing all clinical outsourcing relationships. Dr. Garner presented and moderated Agile’s successful 2019 FDA Advisory Committee meeting. Prior to her tenure at Agile, Dr. Garner was Vice President, Medical Affairs, Women’s Health/Preventive Care at Myriad Genetics. Earlier in her pharmaceutical career, she oversaw all clinical aspects of the global Phase 3 endometriosis development program for Orilissa® at Abbott Laboratories, and while at Merck Research Labs, she was instrumental in a number of NDA submissions for Gardasil. She was also the core presenter and moderator for the successful 2010 FDA Gardasil® Advisory Committee Meeting.